JP2016520515A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520515A5
JP2016520515A5 JP2016501157A JP2016501157A JP2016520515A5 JP 2016520515 A5 JP2016520515 A5 JP 2016520515A5 JP 2016501157 A JP2016501157 A JP 2016501157A JP 2016501157 A JP2016501157 A JP 2016501157A JP 2016520515 A5 JP2016520515 A5 JP 2016520515A5
Authority
JP
Japan
Prior art keywords
group
compound
lower alkyl
heterocycle
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016501157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520515A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/023135 external-priority patent/WO2014150395A1/en
Publication of JP2016520515A publication Critical patent/JP2016520515A/ja
Publication of JP2016520515A5 publication Critical patent/JP2016520515A5/ja
Pending legal-status Critical Current

Links

JP2016501157A 2013-03-15 2014-03-11 抗pcsk9化合物および心血管疾患の治療および/または予防のための方法 Pending JP2016520515A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789867P 2013-03-15 2013-03-15
US61/789,867 2013-03-15
PCT/US2014/023135 WO2014150395A1 (en) 2013-03-15 2014-03-11 Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Publications (2)

Publication Number Publication Date
JP2016520515A JP2016520515A (ja) 2016-07-14
JP2016520515A5 true JP2016520515A5 (https=) 2017-04-13

Family

ID=51580758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501157A Pending JP2016520515A (ja) 2013-03-15 2014-03-11 抗pcsk9化合物および心血管疾患の治療および/または予防のための方法

Country Status (8)

Country Link
US (2) US10131637B2 (https=)
EP (1) EP2968318A4 (https=)
JP (1) JP2016520515A (https=)
CN (1) CN105473141A (https=)
AU (1) AU2014237198A1 (https=)
BR (1) BR112015023193A2 (https=)
CA (1) CA2904662A1 (https=)
WO (1) WO2014150395A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102678074B1 (ko) 2012-05-17 2024-06-26 제넨테크, 인크. 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
US9416110B2 (en) 2012-05-17 2016-08-16 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
ES2588878T3 (es) 2012-05-17 2016-11-07 Array Biopharma, Inc. Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada
HRP20180948T1 (hr) 2012-05-17 2018-08-10 Genentech, Inc. Postupak za proizvodnju aminokiselinskih spojeva
EP3337564A4 (en) 2015-08-21 2019-01-23 Portola Pharmaceuticals, Inc. COMPOSITION AND METHOD FOR THE USE OF TETRAHYDROISOCHINOLINE SMALL MOLECULES FOR THE BINDING AND MODULATION OF PCSK9 PROTEIN ACTIVITY
HK1257102A1 (zh) 2015-08-21 2019-10-11 Portola Pharmaceuticals, Inc. 苯基哌嗪前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)调节剂及其应用
EP3337497B1 (en) 2015-08-21 2023-07-12 SRX Cardio, LLC Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
CN105214087B (zh) 2015-10-29 2017-12-26 陈敏 Pcsk9单克隆抗体在制备治疗炎症免疫性疾病药物中的应用
WO2017087885A1 (en) 2015-11-19 2017-05-26 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
JP7110124B2 (ja) 2016-06-24 2022-08-01 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 心血管疾患を治療するための組成物及び方法
TW201823222A (zh) * 2016-12-23 2018-07-01 財團法人生物技術開發中心 化合物、醫藥組成物及其用途
WO2018165718A1 (en) 2017-03-17 2018-09-20 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of pcsk9
US11497752B2 (en) 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof
US12129284B2 (en) 2018-06-25 2024-10-29 Duke University Compositions and methods for the treatment of cancer characterized with PCSK9 expression
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン/ケキシン9型(pcsk9)阻害剤としての環状ペプチド
PY1998404A (es) 2018-11-27 2021-06-17 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) para el tratamiento de trastornos metabólicos
JP2022507958A (ja) * 2018-11-27 2022-01-18 ノバルティス アーゲー 代謝障害の治療用のプロタンパク質転換酵素サブチリシン/ケキシン9型(pcsk9)阻害薬としての環状四量体化合物
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
EP3969620B1 (en) 2019-05-17 2025-06-25 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
AU2021213811A1 (en) 2020-01-29 2022-07-28 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017313A (en) 1974-09-30 1977-04-12 E. I. Du Pont De Nemours And Company Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process
DE3021590A1 (de) 1980-06-09 1981-12-17 Hoechst Ag, 6000 Frankfurt 4-halogen-5-(halogenmethyl-phenyl)-oxazol-derivate, ein verfahren zu ihrer herstellung und sie enthaltenden strahlungsempfindliche massen
CA2374947A1 (en) 1999-05-24 2000-11-30 Robert M. Scarborough Inhibitors of factor xa
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
US20050288340A1 (en) 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
EP2007717A1 (en) 2006-04-11 2008-12-31 Actelion Pharmaceuticals Ltd. Novel sulfonamide compounds
EA200901376A1 (ru) * 2007-04-13 2010-12-30 Новартис Аг Молекулы и способы модуляции пропротеинконвертазы субтилизинового/кексинового типа 9(pcsk9)
US20090275053A1 (en) 2008-04-30 2009-11-05 Board Of Regents, The University Of Texas System Cell-based pcsk9 screening assay
US9085527B2 (en) * 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
US20110009628A1 (en) * 2009-07-08 2011-01-13 Haiyan Liu Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same
JP5640091B2 (ja) * 2009-10-01 2014-12-10 カディラ・ヘルスケア・リミテッド 脂質異常症および関連疾患の治療のための化合物
WO2012044090A2 (ko) * 2010-09-29 2012-04-05 크리스탈지노믹스(주) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
KR20150059638A (ko) * 2012-05-25 2015-06-01 카타베이시스 파마슈티칼즈, 인코포레이티드 전구단백질 전환효소 섭틸리신/켁신 9형 저하 방법
AR092924A1 (es) 2012-10-09 2015-05-06 Sanofi Sa Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados

Similar Documents

Publication Publication Date Title
JP2016520515A5 (https=)
ES2292770T3 (es) Derivados de fenilpirazoles en calidad de inhibidores de epoxido hidrolasa solubles.
US7872037B2 (en) Antiviral drugs for treatment of arenavirus infection
Suzuki et al. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors
KR102488479B1 (ko) 인플루엔자 바이러스 감염에 사용하기 위한 인돌
CA2698075C (en) Antiviral drugs for treatment of arenavirus infection
KR101426093B1 (ko) 뒤시엔느 근이영양증의 치료
JOP20210017A1 (ar) مثبطات جسيم التهابي nlrp3
Pan et al. 1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors
US8148428B2 (en) Antiviral drugs for treatment of arenavirus infection
ME02696B (me) MODULATORI ORFAN RECEPTORA GAMA KOJI U VEZI SA RETINOIDIMA (ROR-GAMA) ZA UPOTREBU U LEĆENJU AUTOIMUNIH l INFLAMATORNIH BOLESTI
AU2010253820A1 (en) N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation
PE20140836A1 (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide
CN101537001A (zh) 作为jak-stat3信号通路抑制剂的化合物的应用
RU2017112299A (ru) Способ получения ароматического гетероциклического соединения, применяемого в качестве селективного ингибитора киназы jak1, и применение ароматического гетероциклического соединения
HRP20120257T1 (hr) Antagonisti receptora 5-ht7
UY33150A (es) Compuestos carboxamida y su uso como inhibidores v de calpaína
Çıkla et al. Synthesis and evaluation of antiviral, antitubercular and anticancer activities of some novel thioureas derived from 4-aminobenzohydrazide hydrazones
Loksha et al. Synthesis of 2-(aminocarbonylmethylthio)-1H-imidazoles as novel Capravirine analogues
Verma et al. Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors
Lang et al. Discovery of C-5 pyrazole-substituted pyrrolopyridine derivatives as potent and selective inhibitors for janus kinase 1
US10975059B2 (en) Small molecule BRD4 modulators for HIV epigenetic regulation
TWI454445B (zh) 聯苯醯胺衍生小分子之製備與醫藥用途
DK1414444T3 (da) Hidtil ukendte imidasolidinderivater, deres fremstilling og deres anvendelse som VLA-4-antagonister
Yao et al. Design, synthesis and cytotoxic evaluation of novel imatinib amide derivatives that target Abl kinase